| A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours (NCT05154604) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-12-31 |
| A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (NCT04907851) | Redx Pharma Ltd | 2021-12-10 |
| A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours (NCT04949425) | AstraZeneca | 2021-09-13 |
| Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers (NCT04946968) | National Cancer Centre, Singapore | 2021-08-24 |
| A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib (NCT04959266) | AstraZeneca | 2021-06-28 |
| Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis (NCT07737509) | Institute of Cancer Research, United Kingdom | 2021-04-28 |
| Capivasertib China PK Study (NCT04742036) | AstraZeneca | 2021-02-22 |
| A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer (NCT04564027) | AstraZeneca | 2020-12-01 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (NCT04504669) | AstraZeneca | 2020-08-18 |
| IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer (NCT04434482) | Impact Therapeutics, Inc. | 2020-08-07 |
| Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours (NCT04462952) | AstraZeneca | 2020-06-24 |
| Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours (NCT03852823) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-05-23 |
| A Phase 1 Study of [225Ac]-FPI-1434 Injection (NCT03746431) | Fusion Pharmaceuticals Inc. | 2019-01-17 |
| AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (NCT03421353) | AstraZeneca | 2018-02-07 |
| BT1718 in Patients with Advanced Solid Tumours. (NCT03486730) | Cancer Research UK | 2018-01-24 |
| A Study of IMP4297 in Patients With Advanced Solid Tumors (NCT03508011) | Impact Therapeutics, Inc. | 2017-08-23 |
| Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours (NCT03101839) | AstraZeneca | 2017-05-15 |
| Extended Use of ModraDoc006/r (NCT03150368) | Modra Pharmaceuticals | 2017-05-10 |
| The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors (NCT03507543) | Impact Therapeutics, Inc. | 2017-02-03 |
| Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours (NCT02617277) | AstraZeneca | 2015-12-28 |
| Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (NCT02588105) | AstraZeneca | 2015-11-10 |
| A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. (NCT02579226) | AstraZeneca | 2015-10-28 |
| The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. (NCT02430311) | AstraZeneca | 2015-06-10 |
| Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours (NCT02341456) | AstraZeneca | 2015-01-16 |
| Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours (NCT02042781) | Zucero Pty Ltd | 2014-01-01 |
| Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours (NCT01859351) | Heidelberg Pharma AG | 2013-07-01 |
| A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours (NCT01668550) | Cancer Research UK | 2012-10-01 |
| Phase I Study of AT13148, a Novel AGC Kinase Inhibitor (NCT01585701) | Cancer Research UK | 2012-05-01 |
| Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours (NCT01581060) | Heidelberg Pharma AG | 2012-03-01 |
| Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours (NCT01252095) | Zucero Pty Ltd | 2011-01-01 |
| Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours (NCT01163903) | University Health Network, Toronto | 2010-07-01 |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours (NCT01058538) | Philogen S.p.A. | 2005-11-01 |
| Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours (NCT01194193) | AstraZeneca | |